Shaolin Liang

Shaolin Liang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Reproductive Biology and Endocrinology
Verified
Journal Article
Open access
PDF file
JCJingjing Chen
Jingjing Chen
FHFangling Huang
Fangling Huang
JFJing Fu
Jing Fu
JZJianjuan Zhao
Jianjuan Zhao
JLJinsheng Li
Jinsheng Li
YLYanping Li
Yanping Li
Background: Thin endometrium is considered suboptimal for embryo implantation, leading to compromised pregnancy rates without effective therapies. While some studies have reported promoted endometrial growth after a period of hyperbaric oxygen therapy (HBOT) in patients with intrauterine adhesion, there have been no reports in patients with resistant thin endometrium. The purpose of this study was to investigate the impact of HBOT on endometrium growth and pregnancy outcomes in patients with resistant thin endometrium during frozen embryo transfer (FET) treatments. Methods: This prospective pre-post cohort study was conducted at a university-affiliated assisted reproductive medical center between October 2021 and December 2022. Patients who had experienced at least one canceled transfer cycle due to a thin endometrium(< 7 mm) on the endometrium transformation day, despite the use of standard therapies as well as adjuvant therapies, were enrolled in the study. Patients were assigned voluntarily to either the HBOT group or the concurrent control group. The HBOT group received daily HBOT for at least 10 days during the proliferative phase, in addition to the routine endometrium preparation methods and the concurrent control group underwent cycles without HBOT. Propensity score matching (PSM) was used to ensure comparability between the groups. Both self-control and case-control comparisons were conducted. The primary outcome measured was endometrial thickness (ET) on the day of endometrium transformation. Secondary outcomes included intrauterine pregnancy rate (IPR), embryo implantation rate (IR), miscarriage rate, and others. Results: Patients in the HBOT group demonstrated a significantly thicker endometrial thickness on the day of endometrium transformation after undergoing therapy (5.76 ± 1.66 vs. 6.57 ± 1.23, P = 0.002). This improvement was accompanied by a decreased rate of cycle cancellations. Baseline parameters and endometrial thickness were comparable between the HBOT group and the concurrent control group during the cycle. The IPR was similar in patients who received cleavage-stage embryos (0.0% vs. 6.7%, P = 1.00), but significantly higher in patients in the HBOT group who received blastocysts (53.8% vs. 18.2%, P = 0.017). Conclusions: A period of HBOT prior to endometrium transformation contributes to increased endometrial thickness and facilitates blastocyst implantation in patients with resistant thin endometrium during FET treatments. Trial registration: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2300072831, retrospectively registered).

11 July 2024 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
WGWenjun Gu
Wenjun Gu
JWJinhua Wang
Jinhua Wang
YZYunqi Zhang
Yunqi Zhang
SLShaolin Liang
Shaolin Liang
ZAZisheng Ai
Zisheng Ai
JLJiyu Li
Jiyu Li
Background: The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. Objective: The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. Methods: Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. Results: A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. Conclusions: The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.

3 February 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JCJingjing Chen
Jingjing Chen
JZJianjuan Zhao
Jianjuan Zhao
HQHuiyu Qiu
Huiyu Qiu
YLYanhui Liu
Yanhui Liu
YZYunqi Zhang
Yunqi Zhang
JFJing Fu
Jing Fu
Background: Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). Objective: This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. Methods: This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. Results: For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). Conclusions: This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.

30 May 2025 in JMIR Preprints
Verified
Preprint
Open access
JCJingjing Chen
Jingjing Chen
JZJianjuan Zhao
Jianjuan Zhao
HQHuiyu Qiu
Huiyu Qiu
YLYanhui Liu
Yanhui Liu
YZYunqi Zhang
Yunqi Zhang
JFJing Fu
Jing Fu
BACKGROUND Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). OBJECTIVE This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. METHODS This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. RESULTS For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). CONCLUSIONS This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.

25 March 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
JYJing Yu
Jing Yu
YGYangyang Gao
Yangyang Gao
TLTaoran Liu
Taoran Liu
XMXinyang Ma
Xinyang Ma
CWCailin Wu
Cailin Wu
WMWai-Kit Ming
Wai-Kit Ming
Objectives To assess the association between epidural analgesia (EDA) experience and subsequent fertility intention among reproductive-aged individuals with at least one child in China, and to examine whether this relationship varies by region and parity. Design This nationwide cross-sectional study was conducted using multistage stratified and quota sampling across 148 cities in mainland China. Data were analysed using descriptive statistics, generalised linear models and multinomial logistic regression (Mlogit). Setting Community-based data collection conducted across 148 cities in mainland China between 20 June and 31 August 2022. Participants Of 21 872 respondents, 6349 reproductive-aged individuals (females aged 18–49 and males aged 18–65) with at least one child were included after applying standardised data quality criteria. Primary and secondary outcome measures The primary outcome was self-rated fertility intention, operationalised as a continuous measure for regression analysis. The main exposure variable was prior experience with EDA during vaginal birth. Secondary analyses explored variations by region and number of children. Results EDA experience was positively associated with higher fertility intention (β=0.067, 95% CI 0.007 to 0.126, p=0.028). Female respondents reported lower fertility intention compared with males. Regionally, significant positive associations were observed in the central (relative risk ratio (RRR)=1.433, 95% CI 1.011 to 2.032, p=0.043) and western regions (RRR=1.505, 95% CI 1.070 to 2.117, p=0.019). Among women, EDA use was significantly associated with increased fertility intention in primigravida but not in multigravida participants. Conclusions EDA use is positively associated with fertility intention among Chinese reproductive-aged individuals with children. Although this study identifies an association rather than a causal relationship—given the cross-sectional design—it highlights the potential value of improving awareness and access to labour pain management, especially in less developed regions, to better support informed reproductive decision-making and childbirth experiences. Trial registration number ChiCTR2200061046.

18 April 2023 in JMIR Preprints
Verified
Preprint
Open access
WGWenjun Gu
Wenjun Gu
JWJinhua Wang
Jinhua Wang
YZYunqi Zhang
Yunqi Zhang
SLShaolin Liang
Shaolin Liang
ZAZisheng Ai
Zisheng Ai
JLJiyu Li
Jiyu Li
BACKGROUND The significant impact of digital health emerged prominently during the COVID-19 pandemic. Despite this, there is a paucity of bibliometric analyses focusing on technologies within the field of digital health patents. Patents offer a wealth of insights into technologies, commercial prospects, and competitive landscapes, often undisclosed in other publications. Given the rapid evolution of the digital health industry, safeguarding algorithms, software, and advanced surgical devices through patent systems is imperative. The patent system simultaneously acts as a valuable repository of technological knowledge, accessible to researchers. This accessibility facilitates the enhancement of existing technologies and the advancement of medical equipment, ultimately contributing to public health improvement and meeting public demands. OBJECTIVE The primary objective of this study is to gain a more profound understanding of technology hotspots and development trends within the field of digital health. METHODS Using a bibliometric analysis methodology, we assessed the global technological output reflected in patents on digital health published between 2017 and 2021. Using Citespace5.1R8 and Excel 2016, we conducted bibliometric visualization and comparative analyses of key metrics, including national contributions, institutional affiliations, inventor profiles, and technology topics. RESULTS A total of 15,763 digital health patents were identified as published between 2017 and 2021. The China National Intellectual Property Administration secured the top position with 7253 published patents, whereas Koninklijke Philips emerged as the leading institution with 329 patents. Notably, Assaf Govari emerged as the most prolific inventor. Technology hot spots encompassed categories such as “Medical Equipment and Information Systems,” “Image Analysis,” and “Electrical Diagnosis,” classified by Derwent Manual Code. A patent related to the technique of receiving and transmitting data through microchips garnered the highest citation, attributed to the patentee Covidien LP. CONCLUSIONS The trajectory of digital health patents has been growing since 2017, primarily propelled by China, the United States, and Japan. Applications in health interventions and enhancements in surgical devices represent the predominant scenarios for digital health technology. Algorithms emerged as the pivotal technologies protected by patents, whereas techniques related to data transfer, storage, and exchange in the digital health domain are anticipated to be focal points in forthcoming basic research.